We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Galapagos | LSE:GLPG | London | Ordinary Share | BE0003818359 | ORD SHS NO NOMINAL VALUE |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 416.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/4/2013 15:57 | Press Releases 2013 April 22, 2013 Galapagos discovers novel candidate drug to treat breast cancer View English version - Bekijk Nederlandse versie | jammytass | |
04/3/2011 06:46 | glpg > has made large profits and will be one of the worlds leading cmpy traded on euronext, wish they would come back to uk market!!!! | jammytass | |
12/10/2010 06:57 | cancer contract> this cmy will be massive | jammytass | |
04/10/2010 07:39 | more good news for this growing group> oh why oh why did they pull from lse | jammytass | |
20/9/2006 09:56 | Mechelen, Belgium; 19 September 2006 - Galapagos NV (Euronext & LSE: GLPG) has placed 1,305,074 new shares in a successful private placement with Fortis Bank NV, at a price of Eur8.50 per share. Fortis intends to place these new shares with international institutional clients via an accelerated bookbuilding procedure. Galapagos raised gross proceeds of Eur11.1 million. The Board of Directors of Galapagos has authorized this capital increase of ยค11.1 million by the issuance of 1,305,074 new ordinary shares, effective as of 19 September 2006, at a price per share of Eur8.50, reflecting the average share price on Euronext Amsterdam over the last 30 days. The new shares are expected to be admitted to trading and listing on Eurolist by Euronext Brussels and Euronext Amsterdam and on AiM on 22 September 2006. As a result of the placement, Galapagos will have 14,355,817 ordinary shares outstanding. | jonwig | |
06/9/2006 07:50 | Collaboration of BioFocus with a US research unit, revenue of $3m over 2.5 years for GLPG. | jonwig | |
19/7/2006 07:32 | Hi gardenboy. I held some of these for about 1 hour last year, when I took part in their T/O of Biofocus; I always meant to look more closely but never got round to it. Since they (ie. the BioFocus division) are involved in partnering other companies' drug discovery efforts, it may be that the partner takes most of the risk, whilst they take the fees - dunno, like you I haven't done the research. Will come back if I find anything to excite me! A chart since admission to AIM: | jonwig | |
03/4/2006 17:33 | no thread so here's one - invested in a few at 670p - as yet I have done no research ! but simply bought some because the share made a new high and now continues to climb - could be interesting | gardenboy | |
03/4/2006 17:31 | Post removed by ADVFN | Abuse team | |
03/4/2006 17:28 | Company website : | gardenboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions